Treating axial spondyloarthritis.
1.1 Ixekizumab is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy, or active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs), in adults. It is recommended only if:
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and
the company provides ixekizumab according to the commercial arrangement.